scholarly journals Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes

Diabetes Care ◽  
2011 ◽  
Vol 35 (1) ◽  
pp. 4-11 ◽  
Author(s):  
J. Dushay ◽  
C. Gao ◽  
G. S. Gopalakrishnan ◽  
M. Crawley ◽  
E. K. Mitten ◽  
...  
Keyword(s):  
Weight Loss ◽  
Obese Women ◽  
Significant Weight Loss ◽  
Short Term

scholarly journals Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin

2014 ◽  
Vol 170 (3) ◽  
pp. 451-459 ◽  
Author(s):  
Mojca Jensterle Sever ◽  
Tomaz Kocjan ◽  
Marija Pfeifer ◽  
Nika Aleksandra Kravos ◽  
Andrej Janez
Keyword(s):  
Weight Loss ◽  
Body Weight ◽  
Waist Circumference ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Combined Treatment ◽  
Obese Women ◽  
Significant Weight Loss ◽  
Short Term ◽  
Ovary Syndrome

ObjectiveThe effect of metformin on weight reduction in polycystic ovary syndrome (PCOS) is often unsatisfactory. In this study, we investigated the potential add-on effect of treatment with the glucagon-like peptide-1 receptor agonist liraglutide on weight loss in obese nondiabetic women with PCOS who had lost <5% body weight during pretreatment with metformin.MethodsA total of 40 obese women with PCOS, who had been pretreated with metformin for at least 6 months, participated in a 12-week open-label, prospective study. They were randomized to one of three treatment arms: metformin (MET) arm 1000 mg BID, liraglutide (LIRA) arm 1.2 mg QD s.c., or combined MET 1000 mg BID and LIRA (COMBI) 1.2 mg QD s.c. Lifestyle intervention was not actively promoted. The primary outcome was change in body weight.ResultsThirty six patients (aged 31.3±7.1 years, BMI 37.1±4.6 kg/m2) completed the study: 14 on MET, 11 on LIRA, and 11 on combined treatment. COMBI therapy was superior to LIRA and MET monotherapy in reducing weight, BMI, and waist circumference. Subjects treated with COMBI lost on average 6.5±2.8 kg compared with a 3.8±3.7 kg loss in the LIRA group and a 1.2±1.4 kg loss in the MET group (P<0.001). The extent of weight loss was stratified: a total of 38% of subjects were high responders who lost ≥5% body weight, 22% of them in the COMBI arm compared with 16 and 0% in the LIRA and MET arm respectively. BMI decreased by 2.4±1.0 in the COMBI arm compared with 1.3±1.3 in LIRA and 0.5±0.5 in the MET arm (P<0.001). Waist circumference also decreased by 5.5±3.8 cm in the COMBI arm compared with 3.2±2.9 cm in LIRA and 1.6±2.9 cm in the MET arm (P=0.029). Subjects treated with liraglutide experienced more nausea than those treated with metformin, but severity of nausea decreased over time and did not correlate with weight loss.ConclusionsShort-term combined treatment with liraglutide and metformin was associated with significant weight loss and decrease in waist circumference in obese women with PCOS who had previously been poor responders regarding weight reduction on metformin monotherapy.

THE BENEFIT OF SHORT-TERM WEIGHT LOSS WITH ANTI-OBESITY MEDICATIONS IN REAL-WORLD CLINICAL PRACTICE

2019 ◽  
Vol 25 (10) ◽  
pp. 1022-1028
Author(s):  
Kelly Shibuya ◽  
Khawla F. Ali ◽  
Xinge Ji ◽  
Alex Milinoivh ◽  
Janine Bauman ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Weight Loss ◽  
Body Weight ◽  
Body Mass ◽  
Real World ◽  
Significant Weight Loss ◽  
Short Term ◽  
Absolute Weight ◽  
Tertiary Healthcare

Objective: The effectiveness of anti-obesity medications (AOMs) outside of clinical trials is unclear. The objective of this study was to compare the short-term effectiveness of AOMs in real-world practice. Methods: This retrospective study included adults aged ≥18 years, with body mass index ≥30 kg/m2 or ≥27 kg/m2 with at least one obesity-related comorbidity who were prescribed phentermine hydrochloride, phenterminetopiramate, bupropion-naltrexone, or lorcaserin for 12 consecutive weeks between 2006 and 2016 at a large tertiary healthcare system. Propensity score–matched cohorts were created for each pair of AOMs. The primary outcomes were percent and absolute weight loss from baseline after 12 weeks. A prediction model was constructed to estimate weight loss with different AOMs based on demographic and clinical data. Results: Of the 3,411 patients included in this study, patients lost an average of 3.45% of body weight from baseline. All AOMs were associated with a significant weight loss from baseline ( P<.0001). Patients lost the highest percentage of body weight on phentermine hydrochloride (3.75 ± 5.66%), followed by phentermine-topiramate (3.63 ± 5.7%), bupropion-naltrexone (2.66 ± 5.03%), and lorcaserin (1.84 ± 6.69%). In propensity-matched cohorts, patients taking phentermine hydrochloride lost more weight than those taking lorcaserin or bupropion-naltrexone, and patients taking phentermine topiramate lost more weight than patients taking lorcaserin. Conclusion: In real-world practice, AOMs are associated with clinically meaningful weight loss of 2 to 4% after 12 weeks. In this study, phentermine hydrochloride and phentermine topiramate produced the most weight loss. AOMs should be seriously considered as part of the armamentarium to treat patients with obesity. Abbreviations: AOM = anti-obesity medication; BMI = body mass index; EMR = electronic medical record; FDA = Food and Drug Administration; T2D = type 2 diabetes

The effect of weight loss on serum concentrations of nitric oxide induced by short - term exercise in obese women

2009 ◽  
Vol 26 (2) ◽  
pp. 173-182
Author(s):  
M Olszanecka-Glinianowicz ◽  
B Zahorska-Markiewicz ◽  
P Kocełak ◽  
M Plewa ◽  
J Janowska
Keyword(s):  
Nitric Oxide ◽  
Weight Loss ◽  
Serum Concentrations ◽  
Obese Women ◽  
Short Term

scholarly journals Two-Week Isocaloric Time-Restricted Feeding Decreases Liver Inflammation without Significant Weight Loss in Obese Mice with Non-Alcoholic Fatty Liver Disease

2020 ◽  
Vol 21 (23) ◽  
pp. 9156
Author(s):  
Rachel B. Wilson ◽  
Richard Zhang ◽  
Yun Jin Chen ◽  
Kia M. Peters ◽  
Cynthia G. Sawyez ◽  
...  
Keyword(s):  
Weight Loss ◽  
Fatty Liver Disease ◽  
Restricted Feeding ◽  
Liver Inflammation ◽  
Obese Mice ◽  
Significant Weight Loss ◽  
Short Term ◽  
Alcoholic Fatty Liver ◽  
Ad Libitum ◽  
Alcoholic Fatty Liver Disease

Prolonged, isocaloric, time-restricted feeding (TRF) protocols can promote weight loss, improve metabolic dysregulation, and mitigate non-alcoholic fatty liver disease (NAFLD). In addition, 3-day, severe caloric restriction can improve liver metabolism and glucose homeostasis prior to significant weight loss. Thus, we hypothesized that short-term, isocaloric TRF would improve NAFLD and characteristics of metabolic syndrome in diet-induced obese male mice. After 26 weeks of ad libitum access to western diet, mice either continued feeding ad libitum or were provided with access to the same quantity of western diet for 8 h daily, over the course of two weeks. Remarkably, this short-term TRF protocol modestly decreased liver tissue inflammation in the absence of changes in body weight or epidydimal fat mass. There were no changes in hepatic lipid accumulation or other characteristics of NAFLD. We observed no changes in liver lipid metabolism-related gene expression, despite increased plasma free fatty acids and decreased plasma triglycerides in the TRF group. However, liver Grp78 and Txnip expression were decreased with TRF suggesting hepatic endoplasmic reticulum (ER) stress and activation of inflammatory pathways may have been diminished. We conclude that two-week, isocaloric TRF can potentially decrease liver inflammation, without significant weight loss or reductions in hepatic steatosis, in obese mice with NAFLD.

scholarly journals Calcium intake and the outcome of short-term weight management

2008 ◽  
pp. 237-245
Author(s):  
K Kabrnová-Hlavatá ◽  
V Hainer ◽  
M Gojová ◽  
P Hlavatý ◽  
V Kopský ◽  
...  
Keyword(s):  
Weight Loss ◽  
Weight Management ◽  
Calcium Intake ◽  
Epidemiological Studies ◽  
Fat Free Mass ◽  
Obese Women ◽  
Short Term ◽  
Significant Difference ◽  
Eating Inventory

Experimental and epidemiological studies suggest that calcium intake is inversely related to weight gain. Calcium of dairy origin has been shown to be more effective in promoting weight loss. However, clinical studies yielded controversial results concerning the role of calcium intake in weight change. The aim of this study was to ascertain whether the addition of calcium can affect the outcome of 3-week weight management (WM) with a hypocaloric diet characterized by a decreased calcium intake. Overweight/ obese women (n=67; BMI 32.2±4.1 kg/m2; age 49.1±12.1 years) underwent a 4-week comprehensive WM program. WM included a 7 MJ/day diet resulting in a stable weight during the first week and a 4.5 MJ/day diet with mean daily calcium intake 350 mg during the second to fourth week. Participants were divided into three age- and BMI-matched groups who received placebo or calcium (500 mg/day). Calcium was administered either as carbonate or calcium of dairy origin (Lactoval). There was no significant difference in weight loss in response to WM between the placebo-treated and calcium-treated groups. However, addition of calcium to the diet resulted in a lower hunger score in the Eating Inventory as well as a decrease in plasma resistin levels. Body composition measured by bioimpedance demonstrated that added calcium leads to preservation of fat-free mass. Nevertheless, a greater loss of fatfree mass in the placebo group might be partly due to a greater loss of water.

Abstract P222: Sex Moderates Treatment Effects in Integrated Behavior Therapy for Comorbid Obesity and Depression

Circulation ◽  
2020 ◽  
Vol 141 (Suppl_1) ◽  
Author(s):  
Nan Lv ◽  
Lan Xiao ◽  
Lisa Goldman Rosas ◽  
Elizabeth Venditti ◽  
Mark Snowden ◽  
...  
Keyword(s):  
Weight Loss ◽  
Usual Care ◽  
Collaborative Care ◽  
Treatment Effects ◽  
Logistic Models ◽  
Significant Weight Loss ◽  
Short Term ◽  
Short Term Treatment ◽  
Care Intervention ◽  
Clinically Significant

Introduction: Obesity and depression often co-occur, especially in women. Efficacious treatments exist for both conditions, but treatment outcomes vary. Assessing sex-specific responses to integrated therapy of these conditions could inform opportunities for tailoring. Hypothesis: Sex will significantly moderate the effects of an integrated collaborative care intervention on weight loss and depression outcomes through 24 months. Short-term treatment response at 6 months will reliably predict 12- and 24-month outcomes by sex. Methods: We conducted secondary analyses using data from the RAINBOW trial, which demonstrated efficacy of an integrated collaborative care intervention at reducing weight (BMI) and depression severity (SCL-20) at 12 months relative to usual care in adults with obesity and depression. Linear mixed models were used to assess treatment effects by sex, an a priori hypothesized biological moderator, on BMI and SCL-20 at 6, 12, and 24 months. Areas under the receiver operating characteristic curves (AUCs) based on logistic regressions were used to assess sex-specific thresholds of weight loss (%) and SCL-20 reduction at 6 months that reliably predicted clinically significant weight loss (i.e., ≥5% of baseline weight) and depression response (i.e., ≥50% decrease in SCL-20 scores) at 12 and 24 months. Results: Sex significantly moderated the treatment effects on BMI and SCL-20. Compared with women, men achieved significantly greater reductions in BMI at 6, 12, and 24 months in the intervention relative to usual care. Compared with men, women achieved significantly greater reductions in SCL-20 at 12 months only in the intervention relative to usual care. AUCs in the logistic models were similar for both sexes: >0.82 at 12 months and >0.65 at 24 months predicting clinically significant weight loss; >0.70 at 12 months and >0.67 at 24 months predicting clinically significant depression response. With 80% specificity to ensure good probability of correctly identifying participants not achieving longer-term outcomes of clinical significance, women who lost 2.5-3.0% weight and men who lost 3.4-4.1% weight at 6 months were likely to achieve ≥5% weight loss at 12 and 24 months. Similarly, women who reduced SCL-20 by 0.70 and men who reduced by 0.60-0.65 were likely to achieve ≥50% decrease in SCL-20 at 12 and 24 months. Conclusions: The treatment effects of this integrated intervention for obesity and depression differed significantly by sex, with men showing greater weight loss and women showing greater depression reduction. Sex-specific short-term responses at 6 months were identified for predicting clinically significant weight loss and depression outcomes at 12 and 24 months. Results suggest that sex may be an important tailoring variable when designing collaborative care interventions.

Short-Term Carbohydrate-Restricted Diet for Weight Loss in Severely Obese Women

2010 ◽  
Vol 21 (8) ◽  
pp. 1194-1202 ◽  
Author(s):  
Andresa de Toledo Triffoni-Melo ◽  
Ingrid Dick-de-Paula ◽  
Guilherme Vannucchi Portari ◽  
Alceu Afonso Jordao ◽  
Paula Garcia Chiarello ◽  
...  
Keyword(s):  
Weight Loss ◽  
Obese Women ◽  
Restricted Diet ◽  
Short Term ◽  
Severely Obese

scholarly journals Adding cognitive behavioural treatment to either low-carbohydrate or low-fat diets: differential short-term effects

2009 ◽  
Vol 102 (12) ◽  
pp. 1847-1853 ◽  
Author(s):  
Heriberto Rodriguez-Hernandez ◽  
Uziel A. Morales-Amaya ◽  
Ramon Rosales-Valdéz ◽  
Felipe Rivera-Hinojosa ◽  
Martha Rodriguez-Moran ◽  
...  
Keyword(s):  
Weight Loss ◽  
Clinical Intervention ◽  
Obese Women ◽  
Low Fat ◽  
Short Term ◽  
Behavioural Treatment ◽  
Intention To Treat ◽  
Cognitive Behavioural Treatment ◽  
Cognitive Behavioural ◽  
Low Carbohydrate

To evaluate the efficacy of adding cognitive behavioural treatment (CBT) to either a low-carbohydrate (LC) diet or a low-fat (LF) diet in the treatment of weight loss of obese women, a randomised clinical intervention study was performed. A total of 105 healthy non-pregnant obese women (average age and BMI of 45·4 (sd 10·4) years and 36 (sd 4·3) kg/m2) were randomly allocated to the CBT or control (C) groups; within each group, women were randomly selected to receive either the LC or LF diet during 6 months. The pre-planned primary trial end-point was the weight loss. Differences between the groups were assessed using one-way ANOVA. There were three women (2·8 %) who dropped out, all of them in the CBT group. No differences in the anthropometric and laboratory characteristics at baseline were noted between women in the CBT (n 52) and control groups (n 50). Intention-to-treat analysis showed that weight loss in the CBT-LC (90 (sd 12·3) to 82·1 (sd 12·1) kg) and C-LC (89·4 (sd 10·0) to 85·8 (sd 9·8) kg) groups reached 8·7 and 4·0 %, respectively (P < 0·0001), and in the CBT-LF (87·9 (sd 11·4) to 79·4 (sd 11·8) kg) and C-LF (88·8 (sd 14·5) to 85·3 (sd 14·3) kg) groups it was 9·7 and 3·9 %, respectively (P < 0·05). Weight loss was higher in the CBT-LF group than in the CBT-LC groups (P = 0·049). The present results showed that adding CBT to either the LF or LC diet produced significantly greater short-term weight loss in obese women compared with diet alone. These finding support the efficacy of CBT in breaking previous dietary patterns and in developing healthier attitudes that reinforce a healthier lifestyle.

Sign in / Sign up

Export Citation Format

Share Document